CABA · Cabaletta Bio, Inc. · Analyst Estimates
The latest filing states the doubt was alleviated.
“As disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we had previously identified conditions that raised substantial doubt about our ability to continue as a going concern. During the quarter ended September 30, 2026, we raised additional funds through the exercise of common stock warrants for proceeds of $115.0 million and sold 1.9 million shares pursuant to the 2025 ATM Program for net proceeds of $6.0 million. As a result of these cash raises, the conditions that previously raised substantial doubt are no longer present.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Cabaletta Bio, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians. An EPS figure names its accounting basis, GAAP or Non-GAAP, where the capture records one, and compares only with the company's EPS on that basis; without one, the basis is not recorded.
Captured 2026-11-21 15:27 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD · Non-GAAP
Publication date not stated |
-1.41
|
-1.27
|
-1.18
|
6
|
-1.36
|
-1.36
|
-1.36
|
-1.34
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
7
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD · Non-GAAP
Publication date not stated |
-1.54
|
-1.11
|
-0.87
|
6
|
-1.19
|
-1.19
|
-1.48
|
-1.42
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD · Non-GAAP
Publication date not stated |
-0.35
|
-0.27
|
-0.23
|
6
|
-0.31
|
-0.31
|
-0.31
|
-0.32
|
0
|
0
|
1
|
1
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
6
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD · Non-GAAP
Publication date not stated |
-0.36
|
-0.27
|
-0.24
|
6
|
-0.29
|
-0.29
|
-0.29
|
-0.34
|
0
|
0
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
0.00
|
0.00
|
6
|
— | — | — | — | — | — | — | — |